| Name | Title | Contact Details |
|---|---|---|
Garry Wiseman |
Senior Vice President and Chief Digital Officer | Profile |
PrimeMyBody is a global company that helps people to live wellness and create lifestyle. We formulate life-changing products with quality in mind, and that means using nothing but the best nature has to offer. Being healthy isn`t a fad or a trend... instead, it`s a lifestyle, and our goal is to show the world just that.
Civitas Senior Living is a team of senior living experts that provide all facets of senior living operations. This expertise includes extensive experience in Assisted Living, Memory Care, and Independent Living. Through third-party management contracts, Civitas provides expert management services for operational start-ups, turn-around operations, and on-going operations. Civitas Senior Living works closely with developers to optimize operations through developing partnerships that align interests. When contracting with Civitas Senior Living, you are partnering with an experienced operator that is also an owner. This ownership experience provides a proven track record of operating properties with excellent financial returns and high occupancy rates while focusing on customer satisfaction.
P1 Dental Partners is a Dental Partnership Organization that puts patients first, maintains doctor autonomy, and aims for excellence in dentistry. Learn more.
Wellness Resource Group is a Bayport, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.